Table No. 1: Pharmacokinetics of Protease Inhibitors
 
Boosted
Brand
Name		 Generic Name Drug per tab/capsule Unboosted Doses (1) Dose (1) Norvir
100 mg caps
Crixivan
indinavir 200 mg (5)
333 mg (5)
400 mg

XXXXXXX
XXXXXXX
2 caps TID (4)

XXXXXXX
3 caps BID* (2)
2 caps BID		 XXXXXXX
1-2 caps BID*
1-2 caps BID*
Fortovase saquinavir 200 mg 6 caps TID 5 caps BID 1 cap BID
Invirase saquinavir 200 mg
500 mg		 Not recommended
Not recommended 		5 caps BID
2 tabs BID		 1 cap BID
1 cap BID
Kaletra lopinavir/ritonavir 133 mg/33 mg 3 caps BID 4 caps BID* XXXXXXX
Lexiva fosamprenavir 700 mg 2 tabs BID 1 tab BID
2 tabs QD (3,6)		 1 cap BID
2 caps QD
Norvir ritonavir 100 mg 6 caps BID XXXXXXX XXXXXXX
Reyataz atazanavir 150 mg
200 mg		 XXXXXXX
2 caps QD		 2 caps QD (7)
XXXXXXX 		1 cap QD
XXXXXXX
Viracept nelfinavir 250 mg

625 mg

 5 tabs BID
3 tabs TID
2 tabs BID		 Cannot be
boosted with
Norvir		 Cannot be
boosted with
Norvir

*These doses are supported by clinical trials or experience, but are not FDA approved

  1. All doses assume that the product is being used in combination with at least two other active antiretroviral agents
  2. BID = twice a day
  3. QD = once a day
  4. TID = three times a day
  5. These strengths are typically used to complete doses needed to compensate for various drug interactions requiring dose adjustments
  6. Once daily dosing of Lexiva with Norvir is not recommended in patients who are protease inhibitor experienced
  7. Reyataz with Norvir has not been studied in patients receiving HIV treatment for the first time